Treatment of metastatic pancreatic cancer

JNCCN Journal of the National Comprehensive Cancer Network

Volumn 3, Issue 5, 2005, Pages 627-636

  Ko, Andrew H ^a,b   Tempero, Margaret A ^a,b  

^a University of California at San Francisco Comprehensive Cancer Center ^*

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Gemcitabine; Pancreatic cancer; Systemic therapy; Targeted agents

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CETUXIMAB; CISPLATIN; DIPYRIDAMOLE; DOCETAXEL; EPIRUBICIN; ERLOTINIB; EXATECAN; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; IRINOTECAN; MITOMYCIN C; OXALIPLATIN; PEMETREXED; PLATINUM DERIVATIVE; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIMETABOLITE; DEOXYCYTIDINE; DRUG DERIVATIVE;

ARTICLE; CANCER MORTALITY; CANCER STAGING; CANCER SURGERY; CLINICAL TRIAL; DIARRHEA; DRUG APPROVAL; DRUG DELIVERY SYSTEM; DRUG DOSE REGIMEN; DRUG MECHANISM; DRUG POTENTIATION; GASTROINTESTINAL DISEASE; HUMAN; INFECTION; METASTASIS; PANCREAS ADENOCARCINOMA; PATIENT CARE; RASH; STOMATITIS; THROMBOEMBOLISM; TREATMENT OUTCOME; TUMOR GROWTH; ADENOCARCINOMA; PANCREAS TUMOR; PATHOLOGY; PROGNOSIS; REVIEW;

ADENOCARCINOMA; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DEOXYCYTIDINE; HUMANS; PANCREATIC NEOPLASMS; PROGNOSIS;

EID: 33644692858     PISSN: 15401405     EISSN: 15401413     Source Type: Journal    
DOI: 10.6004/jnccn.2005.0036     Document Type: Article

References (59)

1. Jemal A, Murray T, Ward E, et al. Cancer statistics, 2005. CA Cancer J Clin 2005;55:10-30.
2. Moertel CG, Frytak S, Hahn RG, et al. Therapy of locally unresectable pancreatic carcinoma: a randomized comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads + 5-fluorouracil), and high dose radiation + 5-fluorouracil: The Gastrointestinal Tumor Study Group. Cancer 1981;48:1705-1710.
3. Klaassen DJ, MacIntyre JM, Catton GE, et al. Treatment of locally unresectable cancer of the stomach and pancreas: a randomized comparison of 5-fluorouracil alone with radiation plus concurrent and maintenance 5-fluorouracil-an Eastern Cooperative Oncology Group study. J Clin Oncol 1985;3:373-378.
4. Treatment of locally unresectable carcinoma of the pancreas: comparison of combined-modality therapy (chemotherapy plus radiotherapy) to chemotherapy alone. Gastrointestinal Tumor Study Group. J Natl Cancer Inst 1988;80:751-755.
5. Burris HA 3rd, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997;15:2403-2413.
6. Storniolo AM, Enas NH, Brown CA, et al. An investigational new drug treatment program for patients with gemcitabine: results for over 3000 patients with pancreatic carcinoma. Cancer 1999;85:1261-1268.
7. Grunewald R, Kantarjian H, Keating MJ, et al. Pharmacologically directed design of the dose rate and schedule of 2′,2′-difluorodeoxycytidine (Gemcitabine) administration in leukemia. Cancer Res 1990;50:6823-6826.
8. Abbruzzese JL, Grunewald R, Weeks EA, et al. A phase I clinical, plasma, and cellular pharmacology study of gemcitabine. J Clin Oncol 1991;9:491-498.
9. Tempero M, Plunkett W, Ruiz Van Haperen V, et al. Randomized phase II comparison of dose-intense gemcitabine: thirty-minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma. J Clin Oncol 2003;21:3402-3408.
10. Berlin JD, Catalano P, Thomas JP, et al. Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297. J Clin Oncol 2002;20:3270-3275.
11. Herrmann R, Bodoky G, Ruhstaller T, et al. Gemcitabine plus capecitabine versus G alone in locally advanced or metastatic pancreatic cancer. A randomized phase III study of the Swiss Group for Clinical Cancer Research (SAKK) and the Central European Cooperative Oncology Group (CECOG) (Abstr). In: Proceedings of the American Society of Clinical Oncology. Orlando, FL: ASCO; 2005;23:310s.
12. Hess V, Salzberg M, Borner M, et al. Combining capecitabine and gemcitabine in patients with advanced pancreatic carcinoma: a phase I/II trial. J Clin Oncol 2003;21:66-68.
13. Stathopoulos GP, Syrigos K, Polyzos A, et al. Front-line treatment of inoperable or metastatic pancreatic cancer with gemcitabine and capecitabine: an intergroup, multicenter, phase II study. Ann Oncol 2004;15:224-229.
14. Bergman AM, Ruiz van Haperen VW, Veerman G, et al. Synergistic interaction between cisplatin and gemcitabine in vitro. Clin Cancer Res 1996;2:521-230.
15. Kanzawa F, Saijo N. In vitro interaction between gemcitabine and other anticancer drugs using a novel three-dimensional model. Semin Oncol 1997;24:S7-8-S7-16.
16. Kaufman D, Raghavan D, Carducci M, et al. Phase II trial of gemcitabine plus cisplatin in patients with metastatic urothelial cancer. J Clin Oncol 2000;18:1921-1927.
17. Heinemann V, Wilke H, Mergenthaler HG, et al. Gemcitabine and cisplatin in the treatment of advanced or metastatic pancreatic cancer. Ann Oncol 2000;11:1399-403.
18. Philip PA, Zalupski MM, Vaitkevicius VK, et al. Phase II study of gemcitabine and cisplatin in the treatment of patients with advanced pancreatic carcinoma. Cancer 2001;92:569-577.
19. Colucci G, Giuliani F, Gebbia V, et al. Gemcitabine alone or with cisplatin for the treatment of patients with locally advanced and/or metastatic pancreatic carcinoma: a prospective, randomized phase III study of the Gruppo Oncologia dell'Italia Meridionale. Cancer 2002;94:902-910.
20. Heinemann V, Quietzsch D, Gieseler F, et al. A phase III trial comparing gemcitabine plus cisplatin vs. gemcitabine alone in advanced pancreatic carcinoma (Abstr). In: Proceedings of the American Society of Clinical Oncology. Chicago, IL: ASCO; 2003;22:250.
21. Louvet C, Labianca L, Hammel P, et al. GemOx (gemcitabine + oxaliplatin) versus Gem (gemcitabine) in non resectable pancreatic adenocarcinoma: Final results of the GERCOR/GISCAD Intergroup Phase III (Abstr). In: Proceedings of the American Society of Clinical Oncology. New Orleans, LA: ASCO; 2004;23:314.
22. Rocha Lima CM, Green MR, Rotche R, et al. Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate. J Clin Oncol 2004;22:3776-3783.
23. O'Reilly E, Abou-Alfa G, Letourneau R, et al. A randomized phase III trial of DX-8951f (exatecan mesylate; DX) and gemcitabine (GEM) vs. gemcitabine alone in advanced pancreatic cancer. J Clin Oncol 2004;22:4006.
24. Cheverton P, Freiss H, Andras J, et al. Phase III results of exatecan (DX-8951f) versus gemcitabine (Gem) in chemotherapy-naïve patients with advanced pancreatic cancer (APC). J Clin Oncol 2004;22:4005.
25. Richards DA, Kindler HL, Oettle H, et al. A randomized phase III study comparing gemcitabine + pemetrexed versus gemcitabine in patients with locally advanced and metastatic pancreas cancer. J Clin Oncol 2004;22:4007.
26. Kulke MH, Niedzwiecki D, Tempero MA, et al. A randomized phase II study of gemcitabine/cisplatin, gemcitabine fixed dose rate infusion, gemcitabine/docetaxel, or gemcitabine/irinotecan in patients with metastatic pancreatic cancer (CALGB 89904) (Abstr). In: Proceedings of the American Society of Clinical Oncology. New Orleans, LA; ASCO; 2004;23:315.
27. Heinemann V, Hoehler T, Seipelt G, et al. Capecitabine plus Oxaliplatin versus Capecitabine plus Gemcitabine versus Gemcitabine plus Oxaliplatin: A randomized phase II trial in advanced pancreatic cancer (Abstr). In: Proceedings of the American Society of Clinical Oncology. Orlando, FL: ASCO; 2005;23:315s.
28. Rougier P, Adenis A, Ducreux M, et al. A phase II study: docetaxel as first-line chemotherapy for advanced pancreatic adenocarcinoma. Eur J Cancer 2000;36:1016-1025.
29. Cartwright TH, Cohn A, Varkey JA, et al. Phase II study of oral capecitabine in patients with advanced or metastatic pancreatic cancer. J Clin Oncol 2002;20:160-164.
30. Burch PA, Ghosh C, Schroeder G, et al. Phase II evaluation of continuous-infusion 5-fluorouracil, leucovorin, mitomycin-C, and oral dipyridamole in advanced measurable pancreatic cancer: a North Central Cancer Treatment Group Trial. Am J Clin Oncol 2000;23:534-537.
31. Raderer M, Kornek GV, Hejna MH, et al. Treatment of advanced pancreatic cancer with epirubicin, 5-fluorouracil and 1-leucovorin: a phase II study. Ann Oncol 1997;8:797-799.
32. Kurtz JE, Negrier S, Husseini F, et al. A phase II study of docetaxel-irinotecan combination in advanced pancreatic cancer. Hepatogastroenterology 2003;50:567-570.
33. Ducreux M, Mitry E, Ould-Kaci M, et al. Randomized phase II study evaluating oxaliplatin alone, oxaliplatin combined with infusional 5-FU, and infusional 5-FU alone in advanced pancreatic carcinoma patients. Ann Oncol 2004;15:467-473.
34. Conroy T, Paillot B, Francois E, et al. Irinotecan plus oxaliplatin and leucovorin-modulated fluorouracil in advanced pancreatic cancer - A Groupe Tumeurs Digestives of the Federation Nationale des Centres de Lutte Contre le Cancer study. J Clin Oncol 2005;23:1228-1236.
35. Moore MJ, Hamm J, Dancey J, et al. Comparison of gemcitabine versus the matrix metalloproteinase inhibitor BAY 12-9566 in patients with advanced or metastatic adenocarcinoma of the pancreas: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2003;21:3296-3302.
36. Bramhall SR, Rosemurgy A, Brown PD, et al. Marimastat as first-line therapy for patients with unresectable pancreatic cancer: a randomized trial. J Clin Oncol 2001;19:3447-3455.
37. Bramhall SR, Schulz J, Nemunaitis J, et al. A double-blind placebo-controlled, randomised study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancer. Br J Cancer 2002;87:161-167.
38. Van Cutsem E, van de Velde H, Karasek P, et al. Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer. J Clin Oncol 2004;22:1430-1438.
39. Mendelsohn J, Baselga J. Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. J Clin Oncol 2003;21:2787-2799.
40. Murphy LO, Cluck MW, Lovas S, et al. Pancreatic cancer cells require an EGF receptor-mediated autocrine pathway for proliferation in serum-free conditions. Br J Cancer 2001;84:926-935.
41. Yamanaka Y, Friess H, Kobrin MS, et al. Coexpression of epidermal growth factor receptor and ligands in human pancreatic cancer is associated with enhanced tumor aggressiveness. Anticancer Res 1993;13:565-569.
42. Tobita K, Kijima H, Dowaki S, et al. Epidermal growth factor receptor expression in human pancreatic cancer: Significance for liver metastasis. Int J Mol Med 2003;11:305-309.
43. Xiong HQ, Rosenberg A, LoBuglio A, et al. Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor, in combination with gemcitabine for advanced pancreatic cancer: a multicenter phase II Trial. J Clin Oncol 2004;22:2610-2616.
44. Kim TE, Murren JR. Erlotinib OSI/Roche/Genentech. Curr Opin Investig Drugs 2002;3:1385-1395.
45. Dragovich T, Patnaik A, Rowinsky EK, et al. A phase I B trial of gemcitabine and erlotinib HCL in patients with advanced pancreatic adenocarcinoma and other potentially responsive malignancies (Abstr). In: Proceedings of the American Society of Clinical Oncology. Chicago, IL: ASCO; 2003;22:223.
46. Porterfield BW, Dragovich T, Patnaik A, et al. Erlotinib + gemcitabine in patients with unresectable pancreatic carcinoma: results from a phase IB trial (Abstr). J Clin Oncol, 2004 ASCO Annual Meeting Proceedings (Post-Meeting Edition). 2004;22:4110.
47. Moore MJ, Goldstein D, Hamm J, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer. A phase III trial of the National Cancer Institute of Canada Clinical Trials Group (Abstr). In: Proceedings of the American Society of Clinical Oncology. Orlando, FL: ASCO; 2005;23:1.
48. Korc M. Pathways for aberrant angiogenesis in pancreatic cancer. Mol Cancer 2003;2:8.
49. Itakura J, Ishiwata T, Friess H, et al. Enhanced expression of vascular endothelial growth factor in human pancreatic cancer correlates with local disease progression. Clin Cancer Res 1997;3:1309-1316.
50. Itakura J, Ishiwata T, Shen B, et al. Concomitant overexpression of vascular endothelial growth factor and its receptors in pancreatic cancer. Int J Cancer 2000;85:27-34.
51. Luo J, Guo P, Matsuda K, et al. Pancreatic cancer cell-derived vascular endothelial growth factor is biologically active in vitro and enhances tumorigenicity in vivo. Int J Cancer 2001;92:361-369.
52. Ikeda N, Adachi M, Taki T, et al. Prognostic significance of angiogenesis in human pancreatic cancer. Br J Cancer 1999;79:1553-1563.
53. Seo Y, Baba H, Fukuda T, et al. High expression of vascular endothelial growth factor is associated with liver metastasis and a poor prognosis for patients with ductal pancreatic adenocarcinoma. Cancer 2000;88:2239-2245.
54. Hotz HG, Reber HA, Hotz B, et al. Angiogenesis inhibitor TNP-470 reduces human pancreatic cancer growth. J Gastrointest Surg 2001;5:131-138.
55. Kindler HL, Friberg G, Stadler WM, et al. Bevacizumab (B) plus gemcitabine (G) in patient (pts) with advanced pancreatic cancer (PC): Updated results of a multi-center phase II trial (Abstr). In: Proceedings of the American Society of Clinical Oncology. New Orleans, LA: ASCO; 2004;23:314.
56. Almoguera C, Shibata D, Forrester K, et al. Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes. Cell 1988;53:549-554.
57. Hirano T, Shino Y, Saito T, et al. Dominant negative MEKK1 inhibits survival of pancreatic cancer cells. Oncogene 2002;21:5923-5928.
58. Friess H, Berberat P, Schilling M, et al. Pancreatic cancer: the potential clinical relevance of alterations in growth factors and their receptors. J Mol Med 1996;74:35-42.
59. Thayer SP, Di Magliano MP, Heiser PW, et al. Hedgehog is an early and late mediator of pancreatic cancer tumorigenesis. Nature 2003;425:851-856.